Lexaria Bioscience - A global innovator in drug delivery platforms

DehydraTECH™ is technology for improved delivery of bioactive compounds.

Lexaria Bioscience Corp’s (NASDAQ:LEXX, LEXXW) proprietary drug delivery-enabling technology, DehydraTECH™, improves the absorption of active pharmaceutical ingredients (APIs) into the bloodstream, allowing greater drug effectiveness often with reduced side effects.

DehydraTECH is a platform technology that can be applied to many different APIs and other bioactive substances, spanning both small and large molecule therapeutics, in oral formats including tablets, capsules, oral suspensions and more.

For investor information

For licensing opportunities

Companies in various locations around the world are actively using or examining DehydraTECH for incorporation into a broad range of drug and consumer products. Lexaria operates a federally licensed, in-house formulation development and research laboratory and is building a robust intellectual property portfolio with 50 patents granted internationally and many more patents pending worldwide.

Learn More

Lexaria’s disruptive DehydraTECH technology is available to be licensed to improve drug delivery for existing orally administered products or to create revolutionary new ones.

Licensing opportunities

DehydraTECH Commercial Applications

Lexaria’s DehydraTECH has evidenced superior pharmacokinetics and pharmacodynamics across a broad range of small molecules and large molecule therapeutics such as GLP-1 peptide drugs. DehydraTECH is protected by 54 granted patents internationally, with many more patent applications pending, for use with a broad range of drugs and bioactive product formats, including but not limited to solid-oral dosage forms (i.e., tablets, pills, powder-filled capsules, powder filled sachets and dissolvable tablets) and consumable liquids (i.e., oral suspensions).

Pharmaceuticals

LEARN MORE

Non-pharmaceutical

LEARN MORE

Sign up to receive our news and updates

LEXARIA EMAIL ALERTS